Ranbaxy buyout boosts Daiichi profit 10-fold

Daiichi Sankyo posted an April-June recurring profit of 70.1 billion yen (USD 808 million), up from 7.2 billion yen a year earlier.

Ranbaxy to launch Daiichi Sankyo`s drug in Africa

The country`s largest drug maker by sales, Ranbaxy Laboratories, today said it would launch Olmesartan Medoxomil, an anti-hypertensive drug from parent company Daiichi Sankyo`s portfolio, in six African countries.

Ranbaxy to launch Daiichi Sankyo`s drug in Africa

Ranbaxy Laboratories will launch Olmesartan Medoxomil, an anti-hypertensive drug from parent company Daiichi Sankyo`s portfolio, in six African countries.

Daiichi Sankyo to launch Ranbaxy`s drugs in Japan soon

Daiichi Sankyo, which has a
majority stake in Ranbaxy Laboratories, today said it is going
to launch some of Ranbaxy`s generic medicine in the Japanese
market soon.

Daiichi Sankyo moves SC against SAT order on share price

Leading Japanese drug-maker Daiichi Sankyo has challenged the Securities Appellate Tribunal (SAT) judgement that asked it to make an open offer to shareholders of Zenotech Labs at Rs 160 per share.

Ranbaxy to sell Daiichi Sankyo’s innovator products in Mexico

Ranbaxy Laboratories Monday said it would market products from Daiichi Sankyo`s portfolio in Mexico through its Latin America-based subsidiary, Ranbaxy Mexico S A de C V.

Daiichi Sankyo says to delay offer for Zenotech

Japan`s No.3 drugmaker Daiichi Sankyo said on Monday it would again delay its open offer for a 20 percent stake in India`s Zenotech Laboratories after an Indian court asked it to postpone the launch.

Daiichi wins court battle against Mylan and Matrix

Japanese drug major Daiichi Sankyo said today a US Court has ruled in its favour in a patent litigation related to the anti-hypertensive drug, Benicar, against Mylan Inc and its Indian subsidiary, Matrix Laboratories.

Supreme Court allows Daiichi Sankyo open offer for Zenotech

The Supreme Court on Friday allowed Japanese pharma firm Daiichi Sankyo to go ahead with the public offer for an additional 20 percent stake in Zenotech Laboratories.